Dare Bioscience, Inc. (DARE) SEC filings

DARENasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 5/30

$0.66+0.01 (+2.05%)

Close on Nov 13, 2026Market cap $10.05MP/E –Yield –

SEC filings

40 of Dare Bioscience's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Nov 10, 2026	Nov 12, 2026	SEC EDGAR
Proxy statement	DEF 14A	Oct 6, 2026	Oct 6, 2026	SEC EDGAR
Current report	8-K	Sep 28, 2026	Oct 2, 2026	SEC EDGAR
Current report	8-K	Oct 1, 2026	Oct 1, 2026	SEC EDGAR
Current report	8-K	Sep 10, 2026	Sep 11, 2026	SEC EDGAR
Current report	8-K	Sep 9, 2026	Sep 9, 2026	SEC EDGAR
Current report	8-K	Aug 14, 2026	Aug 17, 2026	SEC EDGAR
Current report	8-K	Aug 13, 2026	Aug 13, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 13, 2026	SEC EDGAR
Current report	8-K	Jul 24, 2026	Jul 24, 2026	SEC EDGAR
Current report	8-K	Jul 13, 2026	Jul 17, 2026	SEC EDGAR
Current report	8-K	Jul 13, 2026	Jul 13, 2026	SEC EDGAR
Current report	8-K	Jun 22, 2026	Jun 22, 2026	SEC EDGAR
Current report	8-K	Jun 11, 2026	Jun 12, 2026	SEC EDGAR
Current report	8-K	May 14, 2026	May 18, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 14, 2026	SEC EDGAR
Current report	8-K	May 14, 2026	May 14, 2026	SEC EDGAR
Current report	8-K	May 1, 2026	May 7, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 11, 2026	Apr 28, 2026	SEC EDGAR
Current report	8-K	Apr 22, 2026	Apr 22, 2026	SEC EDGAR
Current report	8-K	Apr 17, 2026	Apr 20, 2026	SEC EDGAR
Current report	8-K	Apr 16, 2026	Apr 17, 2026	SEC EDGAR
Current report	8-K	Apr 10, 2026	Apr 13, 2026	SEC EDGAR
Current report	8-K	Mar 26, 2026	Mar 26, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 26, 2026	SEC EDGAR
Current report	8-K	Mar 16, 2026	Mar 17, 2026	SEC EDGAR
Current report	8-K	Mar 6, 2026	Mar 9, 2026	SEC EDGAR
Current report	8-K	Mar 2, 2026	Mar 2, 2026	SEC EDGAR
Current report	8-K	Jan 23, 2026	Jan 29, 2026	SEC EDGAR
Current report	8-K	Jan 6, 2026	Jan 6, 2026	SEC EDGAR
Current report	8-K	Nov 26, 2025	Dec 1, 2025	SEC EDGAR
Current report	8-K	Nov 13, 2025	Nov 13, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 13, 2025	SEC EDGAR
Current report	8-K	Sep 2, 2025	Sep 2, 2025	SEC EDGAR
Current report	8-K	Aug 14, 2025	Aug 14, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 14, 2025	SEC EDGAR
Current report	8-K	Jul 25, 2025	Jul 25, 2025	SEC EDGAR
Current report	8-K	Jul 18, 2025	Jul 21, 2025	SEC EDGAR
Current report	8-K	Jul 14, 2025	Jul 14, 2025	SEC EDGAR
Current report	8-K	Jul 9, 2025	Jul 9, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Dare Bioscience's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-12 reverse split on Jul 1, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is DARE.

Compare: DARE vs TXMD · DARE vs SXTP · DARE vs EVFM · DARE vs VTGN · DARE vs DNTH

Gross margin53.8% · median 47.7%

Operating margin-813.4% · median -435.1%

Net margin-804.4% · median -400.8%

Company	Revenue	Growth
EVFM	$17.72M	-0.0%
TXMD	$3.75M	+33.9%
VTGN	$2.38M	–
DARE	$1.37M	–
SXTP	$1.11M	+73.2%
DNTH	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 24
Held by institutions: 8.5%
Auditor: HASKELL & WHITE LLP
SEC CIK: 1401914

Advertisement
300 × 250

See a number that looks wrong?